Biomimetic Ghost Nanomedicine-Based Optotheranostics for Cancer
Related Experiment Video
Updated: Jun 24, 2025

Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution
Published on: May 9, 2025
Rajendra Prasad1, Vaskuri G S Jyothi2, Nagavendra Kommineni3
1School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh 221005, India.
Abstract:
Theranostic medicine combines diagnostics and therapeutics, focusing on solid tumors at minimal doses. Optically activated photosensitizers are significant examples owing to their photophysical and chemical properties. Several optotheranostics have been tested that convert light to imaging signals, therapeutic radicals, and heat. Upon light exposure, conjugated photosensitizers kill tumor cells by producing reactive oxygen species and heat or by releasing cancer antigens. Despite clinical trials, these molecularly conjugated photosensitizers require protection from their surroundings and a localized direction for site-specific delivery during blood circulation. Therefore, cell membrane biomimetic ghosts have been proposed for precise and safe delivery of these optically active large molecules, which are clinically relevant because of their biocompatibility, long circulation time, bypass of immune cell recognition, and targeting ability. This review focuses on the role of biomimetic nanoparticles in the treatment and diagnosis of tumors through light-mediated diagnostics and therapy, providing insights into their preclinical and clinical status.
Insights
Biomimetic nanoparticles offer a novel solution for targeted cancer therapy and diagnosis. These cell membrane-based delivery systems protect photosensitizers, enhancing their efficacy in treating solid tumors with light-activated treatments.
Area of Science:
- Theranostic medicine
- Nanomedicine
- Biotechnology
Background:
- Theranostic medicine integrates diagnostics and therapeutics, particularly for solid tumors, using minimal drug doses.
- Optically activated photosensitizers are key components in optotheranostics, converting light into imaging signals, therapeutic radicals, and heat.
- Current photosensitizers require protection and targeted delivery, posing challenges for clinical application.
Purpose of the Study:
- To review the role of biomimetic nanoparticles in light-mediated tumor diagnosis and therapy.
- To explore the preclinical and clinical status of these advanced theranostic systems.
- To highlight the advantages of cell membrane biomimetic ghosts for delivering photosensitizers.
Main Methods:
- Review of existing literature on optotheranostics and biomimetic nanoparticle applications.
- Analysis of photosensitizer properties and their interaction with light for therapeutic and diagnostic purposes.
- Evaluation of cell membrane biomimetic ghosts as delivery vehicles for photosensitizers.
Main Results:
- Biomimetic nanoparticles, utilizing cell membrane ghosts, provide biocompatibility, prolonged circulation, immune evasion, and targeted delivery.
- These nanoparticles protect optically active molecules, enabling site-specific delivery crucial for effective treatment.
- Optotheranostics utilizing these systems demonstrate potential in killing tumor cells via reactive oxygen species, heat, or antigen release.
Conclusions:
- Cell membrane biomimetic ghosts represent a promising strategy for the precise and safe delivery of photosensitizers in theranostic medicine.
- Biomimetic nanoparticles enhance the clinical relevance of optotheranostics for solid tumor treatment and diagnosis.
- Further investigation into their preclinical and clinical status is warranted to fully realize their therapeutic potential.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019